<DOC>
	<DOCNO>NCT01893333</DOCNO>
	<brief_summary>To develope nerve spar radical hysterectomy treatment cervical cancer minimize complication radical hysterectomy maximize quality life evaluate feasibility efficacy prospective randomize trial .</brief_summary>
	<brief_title>The Efficacy Safety Nerve-sparing Radical Hysterectomy Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>Histologically diagnosed cervical cancer FIGO stage IA2IIA Diameter tumor le 4cm exam One hitological type write squamous cell carcinoma , adenocarcinoma , adenosquamous cell carcinoma Age 1870 Performance status ; GOG 01 Normal hematological , hepatic , nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥ 100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5 mg/dL SBOT/SGPT Alkaline phoaphatase &lt; normal X 3 Patient inform consent Exclusion creteria : Small cell carcinoma Unable perform surgery severe underlie medical disease severe heart disease , congestive heart failure/severe pulmonary disease , pulmonary failure/ active bacterial infectio need non oral antibiotic therapy/ associate severe medical disease Prior chemotherapy radiotherapy Severe bladder funtion abnormality Double primary malignant tumor Psychiatric problem Pregnant breast feed status Legally unable participate clinical trial When Doctor 's decision patient unable participate clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>nerve spar radical hysterectomy</keyword>
</DOC>